Sunshine Biopharma Inc Financials

SBFMW

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Sunshine Biopharma Inc (SBFMW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SBFMW FY2025 2026-04-22

Sales growth is real, but an inventory-heavy, low-capex model still cannot cover overhead above gross profit.

FY2025 free cash burn improved to -$5.5M from -$14.2M in FY2024, a much bigger change than the top line delivered. But operating cash flow also improved to -$5.3M even as net loss widened to -$6.0M, showing the relief came from working-capital normalization and lower capex, not from stronger underlying profitability.

This is a low-capital-intensity business: capex was only $174K in FY2025, so most cash burn comes from operations rather than maintaining assets. Gross profit reached $12.3M, but SG&A still ran at $18.5M, which is why margin recovery has not translated into profitability.

The balance sheet is buying time rather than forcing deleveraging: cash of $9.1M still exceeds total liabilities of $7.0M. Yet a current ratio of 4.2x alongside inventory of $13.5M means a large share of near-term liquidity sits in stock, so working capital remains the main place cash can get trapped.

Financial Health Signals

Financial Health Score 47/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sunshine Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Piotroski F-Score Partial

4/8

Sunshine Biopharma Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.89x

For every $1 of reported earnings, Sunshine Biopharma Inc generates $0.89 in operating cash flow (-$5.3M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$36.3M

YoY+4.1%

5Y CAGR+247.7%

10Y CAGR+170.9%

Sunshine Biopharma Inc generated $36.3M in revenue in fiscal year 2025. This represents an increase of 4.1% from the prior year.

EBITDA

-$5.9M

YoY-5.5%

Sunshine Biopharma Inc's EBITDA was -$5.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.5% from the prior year.

Net Income

-$6.0M

YoY-16.4%

Sunshine Biopharma Inc reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 16.4% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$5.5M

YoY+61.2%

Sunshine Biopharma Inc generated -$5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.2% from the prior year.

Cash & Debt

$9.1M

YoY-5.8%

5Y CAGR+55.9%

10Y CAGR+68.0%

Sunshine Biopharma Inc held $9.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+90.1%

Sunshine Biopharma Inc had 5M shares outstanding in fiscal year 2025. This represents an increase of 90.1% from the prior year.

Margins & Returns

Gross Margin

33.8%

YoY+3.2pp

5Y CAGR-30.0pp

Sunshine Biopharma Inc's gross margin was 33.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.2 percentage points from the prior year.

Operating Margin

-17.2%

YoY-0.5pp

5Y CAGR+790.7pp

10Y CAGR+45666.5pp

Sunshine Biopharma Inc's operating margin was -17.2% in fiscal year 2025, reflecting core business profitability. This is down 0.5 percentage points from the prior year.

Net Margin

-16.5%

YoY-1.7pp

5Y CAGR+3882.3pp

10Y CAGR+96758.0pp

Sunshine Biopharma Inc's net profit margin was -16.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.7 percentage points from the prior year.

Return on Equity

-25.9%

YoY-4.1pp

Sunshine Biopharma Inc's ROE was -25.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$604K

YoY-35.3%

5Y CAGR+222.7%

10Y CAGR+52.9%

Sunshine Biopharma Inc invested $604K in research and development in fiscal year 2025. This represents a decrease of 35.3% from the prior year.

Share Buybacks

YoY-100.0%

Sunshine Biopharma Inc spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

$174K

YoY-89.5%

5Y CAGR+171.1%

10Y CAGR+43.3%

Sunshine Biopharma Inc invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.5% from the prior year.

SBFMW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$36.3M+4.1%	$34.9M+44.7%	$24.1M+454.4%	$4.3M+1802.4%	$228K+219.9%	$71K
Cost of Revenue	$24.1M-0.6%	$24.2M+53.6%	$15.8M+494.7%	$2.6M+2148.2%	$118K+355.9%	$26K
Gross Profit	$12.3M+14.9%	$10.7M+27.9%	$8.3M+391.5%	$1.7M+1434.0%	$111K+142.7%	$46K
R&D Expenses	$604K-35.3%	$934K-49.7%	$1.9M+128.6%	$812K+20.8%	$672K+38801.0%	$2K
SG&A Expenses	$18.5M+12.1%	$16.5M+25.6%	$13.1M-54.3%	$28.7M+1025.1%	$2.6M+309.8%	$622K
Operating Income	-$6.2M-7.1%	-$5.8M-21.5%	-$4.8M+82.3%	-$27.0M-1006.5%	-$2.4M-323.0%	-$577K
Interest Expense	$0-100.0%	$9K-93.6%	$137K+248.4%	$39K-88.0%	$329K+95.6%	$168K
Income Tax	$22K+109.2%	-$235K-159.4%	$395K+69.4%	$233K	$0	$0
Net Income	-$6.0M-16.4%	-$5.1M-13.9%	-$4.5M+83.2%	-$26.7M	N/A	-$2.8M
EPS (Diluted)	N/A	$-7.32	$-351.36-19863.6%	$-1.76+63.0%	$-4.76	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$8.1M-5.7%	$8.6M-8.9%	$9.4M+0.1%	$9.4M+5.7%	$8.9M-7.2%	$9.6M+13.7%	$8.4M-9.3%	$9.3M
Cost of Revenue	$5.9M+6.5%	$5.5M-12.5%	$6.3M+6.0%	$6.0M-3.0%	$6.2M-5.1%	$6.5M+16.8%	$5.6M-19.8%	$6.9M
Gross Profit	$2.2M-28.0%	$3.0M-1.5%	$3.1M-10.2%	$3.4M+25.4%	$2.7M-11.7%	$3.1M+7.9%	$2.9M+21.6%	$2.4M
R&D Expenses	$32K-56.8%	$74K-38.4%	$119K-39.2%	$196K-8.8%	$215K+44.2%	$149K+18.1%	$126K-71.0%	$436K
SG&A Expenses	$3.6M-25.8%	$4.8M+15.8%	$4.2M-24.1%	$5.5M+36.0%	$4.0M-22.3%	$5.2M+30.4%	$4.0M+9.6%	$3.6M
Operating Income	-$1.4M+22.0%	-$1.8M-64.7%	-$1.1M+47.1%	-$2.1M-58.6%	-$1.3M+37.9%	-$2.1M-88.6%	-$1.1M+12.8%	-$1.3M
Interest Expense	N/A	$0	$0	$0	$0+100.0%	-$41K	$0-100.0%	$245
Income Tax	$0-100.0%	$408K+397.1%	-$137K+34.3%	-$209K-420.8%	-$40K+68.8%	-$129K-159.8%	$215K+162.6%	-$344K
Net Income	-$1.2M+41.9%	-$2.1M-142.2%	-$884K+50.1%	-$1.8M-50.1%	-$1.2M+45.3%	-$2.2M-80.2%	-$1.2M-142.3%	-$494K
EPS (Diluted)	N/A	N/A	N/A	$-0.82-86.4%	$-0.44	N/A	N/A	$-43.48

SBFMW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$30.1M-1.6%	$30.6M+11.8%	$27.3M-6.5%	$29.2M+1227.5%	$2.2M+110.7%	$1.0M
Current Assets	$26.9M+3.4%	$26.0M+4.3%	$24.9M-8.9%	$27.3M+1143.8%	$2.2M+114.0%	$1.0M
Cash & Equivalents	$9.1M-5.8%	$9.7M-40.5%	$16.3M-25.4%	$21.8M+967.2%	$2.0M+106.6%	$990K
Inventory	$13.5M+19.5%	$11.3M+96.7%	$5.7M+74.3%	$3.3M+3014.0%	$106K+344.4%	$24K
Accounts Receivable	$3.5M-10.6%	$3.9M+51.6%	$2.6M+33.5%	$1.9M+24421.1%	$8K+307.0%	$2K
Goodwill	N/A	$0	$0	$0	$0	N/A
Total Liabilities	$7.0M-0.3%	$7.1M+15.0%	$6.1M-19.4%	$7.6M+282.5%	$2.0M-0.5%	$2.0M
Current Liabilities	$6.4M+2.0%	$6.3M+13.7%	$5.6M-19.9%	$6.9M+7497.4%	$91K-91.3%	$1.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$949K
Total Equity	$23.0M-2.0%	$23.5M+10.8%	$21.2M-1.9%	$21.6M+10118.0%	$212K+122.2%	-$955K
Retained Earnings	-$75.0M-8.7%	-$69.0M-8.0%	-$63.9M-7.6%	-$59.4M-81.9%	-$32.7M-61.5%	-$20.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$27.9M-7.1%	$30.1M-4.5%	$31.5M-1.5%	$32.0M+9.5%	$29.2M-4.5%	$30.6M+1.7%	$30.1M+2.6%	$29.3M
Current Assets	$24.8M-7.7%	$26.9M-4.0%	$28.0M+0.4%	$27.9M+13.8%	$24.5M-5.7%	$26.0M-0.1%	$26.0M+0.9%	$25.7M
Cash & Equivalents	$6.9M-24.2%	$9.1M-2.0%	$9.3M-9.7%	$10.3M+26.8%	$8.1M-16.1%	$9.7M-20.6%	$12.2M+6.1%	$11.5M
Inventory	$13.2M-2.3%	$13.5M-4.2%	$14.1M+8.0%	$13.0M+9.8%	$11.9M+5.1%	$11.3M+14.8%	$9.8M+15.7%	$8.5M
Accounts Receivable	$4.0M+15.9%	$3.5M-16.7%	$4.2M+15.8%	$3.6M+4.1%	$3.4M-10.9%	$3.9M+20.2%	$3.2M-19.0%	$4.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Total Liabilities	$6.4M-8.9%	$7.0M-3.4%	$7.3M+16.0%	$6.3M-3.1%	$6.5M-8.1%	$7.1M+40.7%	$5.0M-13.7%	$5.8M
Current Liabilities	$5.9M-8.8%	$6.4M-3.1%	$6.7M+19.3%	$5.6M-3.3%	$5.8M-8.7%	$6.3M+39.4%	$4.5M-14.5%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$21.5M-6.6%	$23.0M-4.8%	$24.2M-5.8%	$25.7M+13.1%	$22.7M-3.4%	$23.5M-6.1%	$25.0M+6.6%	$23.5M
Retained Earnings	-$76.3M-1.7%	-$75.0M-2.9%	-$72.9M-1.2%	-$72.0M-2.5%	-$70.2M-1.7%	-$69.0M-3.2%	-$66.9M-1.8%	-$65.7M

SBFMW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.3M+57.4%	-$12.5M-42.7%	-$8.8M-67.2%	-$5.2M-186.9%	-$1.8M-178.3%	-$657K
Capital Expenditures	$174K-89.5%	$1.7M+1914.6%	$82K-57.6%	$194K	$0-100.0%	$1K
Free Cash Flow	-$5.5M+61.2%	-$14.2M-60.1%	-$8.9M-62.7%	-$5.4M-197.5%	-$1.8M-177.8%	-$658K
Investing Cash Flow	-$836K+57.7%	-$2.0M-201.7%	-$656K+95.5%	-$14.6M	$0+100.0%	-$1K
Financing Cash Flow	$4.7M-46.9%	$8.9M+161.0%	$3.4M-91.3%	$39.5M+1258.7%	$2.9M+80.6%	$1.6M
Dividends Paid	N/A	$0	$0	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$3.1M+480.2%	$541K	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.1M-28.2%	-$1.6M-122.0%	-$728K+43.7%	-$1.3M+23.8%	-$1.7M+50.2%	-$3.4M-151.0%	-$1.4M+70.4%	-$4.6M
Capital Expenditures	$5K+593.6%	-$1K-112.9%	$8K-95.0%	$160K+2036.2%	$7K-92.7%	$103K-80.2%	$517K-46.9%	$975K
Free Cash Flow	-$2.1M-28.5%	-$1.6M-119.8%	-$736K+49.3%	-$1.5M+14.7%	-$1.7M+51.5%	-$3.5M-87.2%	-$1.9M+66.3%	-$5.6M
Investing Cash Flow	-$105K-108.2%	-$50K+57.6%	-$118K+74.0%	-$456K-115.0%	-$212K-116.9%	-$98K+85.4%	-$671K-23.7%	-$542K
Financing Cash Flow	$0-100.0%	$725K+859.1%	$76K-97.9%	$3.6M+911.3%	$355K-78.0%	$1.6M-17.2%	$2.0M+6935.5%	-$29K
Dividends Paid	N/A	N/A	$0	$0	$0	$0	$0	$0
Share Buybacks	N/A	$0	$0	$0	$0	$0	$0	$0

SBFMW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	33.8%+3.2pp	30.6%-4.0pp	34.6%-4.4pp	39.0%-9.4pp	48.4%-15.4pp	63.8%
Operating Margin	-17.2%-0.5pp	-16.7%+3.2pp	-19.9%+601.5pp	-621.3%+446.9pp	-1068.2%-260.4pp	-807.8%
Net Margin	-16.5%-1.7pp	-14.7%+4.0pp	-18.7%+596.7pp	-615.4%	N/A	-3898.7%
Return on Equity	-25.9%-4.1pp	-21.9%-0.6pp	-21.3%+102.4pp	-123.7%	N/A	N/A
Return on Assets	-19.9%-3.1pp	-16.8%-0.3pp	-16.5%+75.0pp	-91.5%	N/A	-266.3%
Current Ratio	4.17+0.1	4.11-0.4	4.48+0.5	3.94-20.1	24.07+23.1	0.98
Debt-to-Equity	0.310.0	0.30+0.0	0.29-0.1	0.35-9.1	9.41+10.4	-0.99
FCF Margin	-15.2%+25.5pp	-40.7%-3.9pp	-36.8%+88.5pp	-125.2%+675.5pp	-800.8%+121.4pp	-922.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	27.0%-8.4pp	35.3%+2.7pp	32.6%-3.7pp	36.4%+5.7pp	30.7%-1.6pp	32.2%-1.7pp	34.0%+8.6pp	25.3%
Operating Margin	-17.3%+3.6pp	-20.9%-9.3pp	-11.5%+10.3pp	-21.8%-7.3pp	-14.6%+7.2pp	-21.8%-8.6pp	-13.1%+0.5pp	-13.6%
Net Margin	-15.4%+9.6pp	-25.0%-15.6pp	-9.4%+9.4pp	-18.8%-5.6pp	-13.3%+9.2pp	-22.5%-8.3pp	-14.2%-8.9pp	-5.3%
Return on Equity	-5.8%+3.5pp	-9.3%-5.6pp	-3.6%+3.2pp	-6.9%-1.7pp	-5.2%+4.0pp	-9.2%-4.4pp	-4.8%-2.7pp	-2.1%
Return on Assets	-4.5%+2.7pp	-7.1%-4.3pp	-2.8%+2.7pp	-5.5%-1.5pp	-4.0%+3.0pp	-7.1%-3.1pp	-4.0%-2.3pp	-1.7%
Current Ratio	4.22+0.0	4.17-0.0	4.20-0.8	5.00+0.7	4.25+0.1	4.11-1.6	5.74+0.9	4.86
Debt-to-Equity	0.300.0	0.310.0	0.30+0.1	0.24-0.0	0.29-0.0	0.30+0.1	0.20-0.0	0.25
FCF Margin	-25.7%-6.8pp	-18.9%-11.0pp	-7.8%+7.6pp	-15.4%+3.7pp	-19.1%+17.4pp	-36.6%-14.3pp	-22.2%+37.5pp	-59.7%

Similar Companies

Biofrontera BFRIW

Clever Leaves Holdings Inc CLVRW

Sunshine Biopharma Inc SBFM

$4.4M

Inmed Pharmaceuticals Inc INM

$8.8M

Aytu Biopharma Inc AYTU

$24.1M

Frequently Asked Questions

What is Sunshine Biopharma Inc's annual revenue?

Sunshine Biopharma Inc (SBFMW) reported $36.3M in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sunshine Biopharma Inc's revenue growing?

Sunshine Biopharma Inc (SBFMW) revenue grew by 4.1% year-over-year, from $34.9M to $36.3M in fiscal year 2025.

Is Sunshine Biopharma Inc profitable?

No, Sunshine Biopharma Inc (SBFMW) reported a net income of -$6.0M in fiscal year 2025, with a net profit margin of -16.5%.

What is Sunshine Biopharma Inc's EBITDA?

Sunshine Biopharma Inc (SBFMW) had EBITDA of -$5.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sunshine Biopharma Inc's gross margin?

Sunshine Biopharma Inc (SBFMW) had a gross margin of 33.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sunshine Biopharma Inc's operating margin?

Sunshine Biopharma Inc (SBFMW) had an operating margin of -17.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Sunshine Biopharma Inc's net profit margin?

Sunshine Biopharma Inc (SBFMW) had a net profit margin of -16.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sunshine Biopharma Inc's return on equity (ROE)?

Sunshine Biopharma Inc (SBFMW) has a return on equity of -25.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sunshine Biopharma Inc's free cash flow?

Sunshine Biopharma Inc (SBFMW) generated -$5.5M in free cash flow during fiscal year 2025. This represents a 61.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sunshine Biopharma Inc's operating cash flow?

Sunshine Biopharma Inc (SBFMW) generated -$5.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sunshine Biopharma Inc's total assets?

Sunshine Biopharma Inc (SBFMW) had $30.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sunshine Biopharma Inc's capital expenditures?

Sunshine Biopharma Inc (SBFMW) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sunshine Biopharma Inc spend on research and development?

Sunshine Biopharma Inc (SBFMW) invested $604K in research and development during fiscal year 2025.

How many shares does Sunshine Biopharma Inc have outstanding?

Sunshine Biopharma Inc (SBFMW) had 5M shares outstanding as of fiscal year 2025.

What is Sunshine Biopharma Inc's current ratio?

Sunshine Biopharma Inc (SBFMW) had a current ratio of 4.17 as of fiscal year 2025, which is generally considered healthy.

What is Sunshine Biopharma Inc's debt-to-equity ratio?

Sunshine Biopharma Inc (SBFMW) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sunshine Biopharma Inc's return on assets (ROA)?

Sunshine Biopharma Inc (SBFMW) had a return on assets of -19.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sunshine Biopharma Inc's cash runway?

Based on fiscal year 2025 data, Sunshine Biopharma Inc (SBFMW) had $9.1M in cash against an annual operating cash burn of $5.3M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sunshine Biopharma Inc's Piotroski F-Score?

Sunshine Biopharma Inc (SBFMW) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sunshine Biopharma Inc's earnings high quality?

Sunshine Biopharma Inc (SBFMW) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sunshine Biopharma Inc?

Sunshine Biopharma Inc (SBFMW) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.